Maloprim is developed by Imperial College London.

What development phase is Maloprim in?

Maloprim is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Maloprim

Imperial College London · FDA-approved active Small molecule Quality 0/100

Maloprim, developed by Imperial College London, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the credibility of Imperial College London. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	Maloprim
Sponsor	Imperial College London
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Early Childhood Malaria Prevention With Maloprim in The Gambia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Maloprim CI brief — competitive landscape report
Maloprim updates RSS · CI watch RSS
Imperial College London portfolio CI